MCID: LVR013
MIFTS: 72

Liver Disease

Categories: Gastrointestinal diseases, Liver diseases, Genetic diseases, Rare diseases, Metabolic diseases

Aliases & Classifications for Liver Disease

Summaries for Liver Disease

MedlinePlus : 41 your liver is the largest organ inside your body. it helps your body digest food, store energy, and remove poisons. there are many kinds of liver diseases: diseases caused by viruses, such as hepatitis a, hepatitis b, and hepatitis c diseases caused by drugs, poisons, or too much alcohol. examples include fatty liver disease and cirrhosis. liver cancer inherited diseases, such as hemochromatosis and wilson disease symptoms of liver disease can vary, but they often include swelling of the abdomen and legs, bruising easily, changes in the color of your stool and urine, and jaundice, or yellowing of the skin and eyes. sometimes there are no symptoms. tests such as imaging tests and liver function tests can check for liver damage and help to diagnose liver diseases.

MalaCards based summary : Liver Disease, also known as liver diseases, is related to alpha 1-antitrypsin deficiency and congenital dyserythropoietic anemia, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Liver Disease is SERPINA1 (Serpin Family A Member 1), and among its related pathways/superpathways are Metabolism and Adipogenesis. The drugs Amlodipine and Perindopril have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 72 Liver disease (also called hepatic disease) is a type of damage to or disease of the... more...

Related Diseases for Liver Disease

Diseases in the Liver Disease family:

Infantile Liver Failure Syndrome 2 Infantile Liver Failure Syndrome 1
Liver Failure, Transient Infantile Acute Liver Failure

Diseases related to Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 501)
id Related Disease Score Top Affiliating Genes
1 alpha 1-antitrypsin deficiency 32.7 ALB CYP2E1 F2 PNPLA3 SLC17A5
2 congenital dyserythropoietic anemia 32.1 ALB TNF
3 alcoholic liver cirrhosis 31.6 CYP2E1 GGT1 GPT SLC17A5
4 lymphoma 30.6 ALB DLAT TNF
5 megaloblastic anemia 30.3 GPT SLC17A5 TNF
6 inherited metabolic disorder 30.2 ADIPOQ INS TNF
7 hepadnavirus infection 30.0 ALB F2 GPT SLC17A5 TNF
8 hepatocellular carcinoma 30.0 AFP ALB CYP2E1 F2 FAH GGT1
9 hereditary hemorrhagic telangiectasia 29.8 AFP ALB F2 GGT1 GPT SLC17A5
10 fatty liver disease 12.4
11 polycystic liver disease 12.2
12 interstitial lung and liver disease 12.0
13 fatty liver disease, nonalcoholic 1 12.0
14 polycystic liver disease 1 12.0
15 polycystic liver disease 2 11.9
16 hepatic failure, early-onset, and neurologic disorder due to cytochrome c oxidase deficiency 11.9
17 dystonia/parkinsonism, hypermanganesemia, polycythemia, and chronic liver disease 11.9
18 fatty liver disease, nonalcoholic 2 11.8
19 pnpla3-related susceptibility to nonalchoholic fatty liver disease 11.7
20 recurrent hepatitis c virus induced liver disease in liver transplant recipients 11.7
21 nonalcoholic steatohepatitis 11.6
22 alcoholic hepatitis 11.5
23 mitochondrial dna depletion syndrome 4a 11.5
24 bile acid synthesis defect, congenital, 1 11.1
25 bile acid synthesis defect, congenital, 2 11.1
26 cholestasis, progressive familial intrahepatic 1 11.1
27 wilson disease 11.0
28 hemochromatosis 11.0
29 chronic fungal otitis externa 11.0 F2 INS
30 htra1-related autosomal dominant cerebral small vessel disease 11.0 GPT SLC17A5
31 non-hodgkin lymphoma, during pregnancy 11.0 ALB F2
32 bile acid synthesis defect, congenital, 4 11.0
33 argyria 11.0 F2 GPT
34 hepatitis c 11.0
35 uterine corpus cancer 11.0 ADIPOQ INS PNPLA3
36 quinquaud's decalvans folliculitis 11.0 GPT SLC17A5
37 hyperlipoproteinemia type iv 11.0 ADIPOQ ALB INS
38 ovarian clear cell malignant adenofibroma 10.9 ADIPOQ INS PNPLA3 SERPINA1
39 pericholangitis 10.9 ABCB4 DLAT TNF
40 bladder sarcoma 10.9 ALB GPT TNF
41 clear cell variant infiltrating bladder urothelial carcinoma 10.9 AFP SERPINA1
42 autoimmune disease of cardiovascular system 10.9 ABCB4 ALB DLAT
43 cholestasis, benign recurrent intrahepatic 10.9 ABCB11 ABCB4 GGT1
44 diabetic encephalopathy 10.9 ADIPOQ INS TNF
45 periampullary adenoma 10.9 ADIPOQ INS TNF
46 polymyositis 10.9 AFP SERPINA1
47 dysfibrinogenemia 10.9
48 dentinogenesis imperfecta 10.9 ALB F2 TNF
49 campylobacteriosis 10.9 ABCB4 GGT1 GPT
50 nasal cavity carcinoma in situ 10.9 ALB SERPINA1 TNF

Comorbidity relations with Liver Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Ischemic Heart Disease
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Liver Disease:



Diseases related to Liver Disease

Symptoms & Phenotypes for Liver Disease

UMLS symptoms related to Liver Disease:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, hepatosplenomegaly, icterus, nausea and vomiting, liver tender, digestive system symptom, gastrointestinal gas, abnormal bruising

MGI Mouse Phenotypes related to Liver Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 ABCB11 ABCB4 ADIPOQ AFP ALB CYP2E1
2 growth/size/body region MP:0005378 10.1 ABCB11 ABCB4 ADIPOQ F2 FAH GGT1
3 liver/biliary system MP:0005370 9.97 AFP ALB CYP2E1 FAH HGF HSD3B7
4 mortality/aging MP:0010768 9.83 CYP2E1 F2 FAH GGT1 HGF HSD3B7
5 neoplasm MP:0002006 9.17 ABCB4 ADIPOQ AFP ALB CYP2E1 FAH

Drugs & Therapeutics for Liver Disease

Drugs for Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1270)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amlodipine Approved Phase 4,Phase 1 88150-42-9 2162
2
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
3
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
4
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128-13-2 31401
5
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
6
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 134678-17-4 60825
7
Caspofungin Approved Phase 4,Phase 3 179463-17-3, 162808-62-0 468682 2826718
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
9
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1 57-27-2 5288826
10
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 143491-57-0 60877
11
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
12
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
13
Ezetimibe Approved Phase 4,Phase 2,Phase 1 163222-33-1 150311
14
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 142340-99-6 60871
15
Magnesium oxide Approved Phase 4 1309-48-4 14792
16
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 198153-51-4 5360545
17
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 36791-04-5 37542
18
Insulin Glargine Approved Phase 4,Phase 2 160337-95-1
19
Insulin-glulisine Approved Phase 4 207748-29-6
20
Zinc Approved Phase 4,Phase 3,Phase 2 7440-66-6 32051 23994
21
Lactulose Approved Phase 4,Phase 3,Phase 2,Phase 1 4618-18-2 11333
22
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
23
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
24
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 3424-98-4 159269
25
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 55981-09-4 41684
26
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
27
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1 64-17-5 702
28
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 80621-81-4 6436173
29
Erythromycin Approved, Vet_approved Phase 4,Phase 1 114-07-8 12560
30
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1 99210-65-8, 215647-85-1
31
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
32
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2 2216-51-5 16666
33
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 128794-94-5 5281078
34
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 24280-93-1 446541
35
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 525-66-6 4946
36
Nadolol Approved Phase 4,Phase 3 42200-33-9 39147
37
Spironolactone Approved Phase 4,Phase 2,Phase 3 1952-01-7, 52-01-7 5833
38
Carvedilol Approved, Investigational Phase 4,Phase 3 72956-09-3 2585
39
Losartan Approved Phase 4,Phase 3,Phase 2 114798-26-4 3961
40
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 26787-78-0 33613 2171
41
Azithromycin Approved Phase 4,Phase 2 83905-01-5 55185 53477736 447043
42
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
43
Cefoxitin Approved Phase 4 35607-66-0 441199
44
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 1,Early Phase 1 85721-33-1 2764
45
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
46
Vancomycin Approved Phase 4,Phase 3 1404-90-6 441141 14969
47
Isosorbide Dinitrate Approved Phase 4 87-33-2 6883
48
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1 10102-43-9 145068
49
Prazosin Approved Phase 4,Phase 2 19216-56-9 4893
50
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385

Interventional clinical trials:

(show top 50) (show all 7584)

id Name Status NCT ID Phase Drugs
1 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
2 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
3 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
4 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
5 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
6 Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure Unknown status NCT01968395 Phase 4 Caspofungin 70 mg
7 The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme Unknown status NCT01429779 Phase 4 Movicol
8 Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Unknown status NCT00155376 Phase 4 morphine and glucagon
9 Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis Unknown status NCT02335632 Phase 4 Probiotics (Lacidofil®);Placebo
10 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
11 A Study of Thymoglobulin and Tacrolimus in Liver Transplant Unknown status NCT00564538 Phase 4 anti-thymocyte globulin (rabbit);tacrolimus
12 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
13 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
14 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
15 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
16 Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients Unknown status NCT02327715 Phase 4 Emtricitabine
17 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
18 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
19 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
20 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
21 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
22 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
23 Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
24 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
25 Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP) Unknown status NCT00761098 Phase 4 Standard Care;Experimental
26 Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
27 HIV Persistence and Viral Reservoirs Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
28 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE) Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
29 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
30 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
31 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
32 Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc) Unknown status NCT00736463 Phase 4 Simvastatin;Atorvastatin 80 mg
33 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
34 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
35 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
36 TO Compare the Triple Drug Therapy and Dual Therapy . Unknown status NCT02075242 Phase 4 Mycophenolate Mofetil;Tacrolimus
37 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4 propranolol
38 Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding Unknown status NCT00567216 Phase 4 Nadolol
39 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
40 Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis Unknown status NCT01693679 Phase 4 Telbivudine, Lamivudine, Adefovir ,Enecavir
41 Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis Unknown status NCT00332904 Phase 4 propranolol;spironolactone
42 Echocardiographic Assessment of Intrapulmonary Vasodilatation: Agitated Saline Versus Polygeline Unknown status NCT00343122 Phase 4
43 Rifaximin Predicts the Complications of Decompensated Cirrhosis Unknown status NCT02074280 Phase 4 rifaximin
44 RCT of Carvedilol Versus Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage Unknown status NCT01070641 Phase 4 Carvedilol
45 Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
46 Cholestatic Drug-induced Liver Injury Unknown status NCT01141322 Phase 4 Ursodeoxycholic Acid;Placebo
47 Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria Unknown status NCT01570075 Phase 4
48 Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
49 Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
50 Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis Unknown status NCT01282398 Phase 4 Simvastatin;placebo

Search NIH Clinical Center for Liver Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Disease cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: liver diseases

Genetic Tests for Liver Disease

Genetic tests related to Liver Disease:

id Genetic test Affiliating Genes
1 Hepatic Failure 29
2 Abnormality of the Liver 29

Anatomical Context for Liver Disease

MalaCards organs/tissues related to Liver Disease:

39
Liver, Testes, Kidney, T Cells, Bone, Lung, Bone Marrow

Publications for Liver Disease

Articles related to Liver Disease:

(show top 50) (show all 3802)
id Title Authors Year
1
Nonalcoholic steatohepatitis and gut microbiota: Future perspectives on probiotics in metabolic liver diseases. ( 28936971 )
2017
2
ER stress-mediated cell damage contributes to the release of EDA(+) fibronectin from hepatocytes in nonalcoholic fatty liver disease. ( 28397039 )
2017
3
Autoimmune acute liver failure and seronegative autoimmune liver disease in children: Are they different from classical disease? ( 28914695 )
2017
4
Neisseria meningitidis and purpura fulminans in a woman with chronic liver disease. ( 28346185 )
2017
5
Roles of silent information regulator 1-serine/arginine-rich splicing factor 10-lipin 1 axis in the pathogenesis of alcohol fatty liver disease. ( 28467182 )
2017
6
NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk. ( 28526997 )
2017
7
Identification of Potential Plasma Biomarkers for Nonalcoholic Fatty Liver Disease by Integrating Transcriptomics and Proteomics in Laying Hens. ( 28077733 )
2017
8
Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease. ( 28533672 )
2017
9
Endoglin in human liver disease and murine models of liver fibrosis - a protective factor against liver fibrosis. ( 28941022 )
2017
10
Associations of Fatty Liver Disease with Hypertension, Diabetes, and Dyslipidemia: Comparison between Alcoholic and Nonalcoholic Steatohepatitis. ( 28912806 )
2017
11
Transarterial Embolization for Treatment of Symptomatic Polycystic Liver Disease: More than 2-year Follow-up. ( 28776546 )
2017
12
QT prolongation is associated with increased mortality in end stage liver disease. ( 28515853 )
2017
13
An extended fatty liver index to predict non-alcoholic fatty liver disease. ( 28089502 )
2017
14
Probiotic mixture improves fatty liver disease by virtue of its action on lipid profiles, leptin, and inflammatory biomarkers. ( 28086768 )
2017
15
Liver Transplantation for Polycystic Liver Disease Due to Huge Liver With Related Complications: A Case Report. ( 28340841 )
2017
16
Hyperinsulinaemic hypoglycaemia, renal Fanconi syndrome and liver disease due to a mutation in the HNF4A gene. ( 28458902 )
2017
17
Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. ( 28523578 )
2017
18
Higher free triiodothyronine is associated with non-alcoholic fatty liver disease in euthyroid subjects: the Lifelines Cohort Study. ( 28081779 )
2017
19
Bariatric Surgery and Liver Function Tests in Nonalcoholic Fatty Liver Disease. ( 28091896 )
2017
20
Vitamin D Is Associated with Severity and Mortality of Non-alcoholic Fatty Liver Disease: A US Population-based Study. ( 28936398 )
2017
21
Waitlisted Candidates With Polycystic Liver Disease are More Likely to be Transplanted Than Those With Chronic Liver Failure. ( 28296808 )
2017
22
Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress. ( 27639593 )
2017
23
Letter: Helicobacter pylori-related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia. ( 28074504 )
2017
24
Center is an important indicator for choice of invasive therapy in polycystic liver disease. ( 27732751 )
2017
25
Intestinal fungi contribute to development of alcoholic liver disease. ( 28530644 )
2017
26
New botanical drug, HL tablet, reduces hepatic fat as measured by magnetic resonance spectroscopy in patients with nonalcoholic fatty liver disease: A placebo-controlled, randomized, phase II trial. ( 28932090 )
2017
27
Role of serum level and genetic variation of IL-28B in interferon responsiveness and advanced liver disease in chronic hepatitis C patients. ( 28214926 )
2017
28
Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis. ( 28953675 )
2017
29
Changes induced by non-alcoholic fatty liver disease in liver sinusoidal endothelial cells and hepatocytes: spectroscopic imaging of single live cells at the subcellular level. ( 28944783 )
2017
30
Modulation of the gut microbiota impacts non-alcoholic fatty liver disease: a potential role for bile acids. ( 28533304 )
2017
31
Cirrhotic cardiomyopathy: is there any correlation between the stage of cardiac impairment and the severity of liver disease? ( 28245727 )
2017
32
Association between Nicotinamide Phosphoribosyltransferase and De Novo Lipogenesis in Non-alcoholic Fatty Liver Disease. ( 28092906 )
2017
33
Prevalence and predictors of liver disease in HIV-infected children and adolescents. ( 28951598 )
2017
34
Energy-matched moderate and high intensity exercise training improves nonalcoholic fatty liver disease risk independent of changes in body mass or abdominal adiposity - a randomized trial. ( 28941598 )
2017
35
Isolated polycystic liver disease genes define effectors of polycystin-1 function. ( 28862642 )
2017
36
Anti-TNFI+ Treatment in Children and Adolescents With Combined Inflammatory Bowel Disease and Autoimmune Liver Disease. ( 28953529 )
2017
37
Additive effect of non-alcoholic fatty liver disease on the development of diabetes in individuals with metabolic syndrome. ( 28527304 )
2017
38
Taurocholate induces biliary differentiation of liver progenitor cells causing hepatic stellate cell chemotaxis in the Ductular Reaction: Role in pediatric cystic fibrosis liver disease. ( 28935574 )
2017
39
Letter: Helicobacter pylori-related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia - authors' reply. ( 28074505 )
2017
40
Animal Models of Nonalcoholic Fatty Liver Disease-A Starter's Guide. ( 28953222 )
2017
41
Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments. ( 28946785 )
2017
42
High free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independently of obesity and insulin resistance. ( 28487551 )
2017
43
Candidate genes investigation for severe nonalcoholic fatty liver disease based on bioinformatics analysis. ( 28796060 )
2017
44
Insulin-like growth factor 1 and metabolic parameters are associated with nonalcoholic fatty liver disease in obese children and adolescents. ( 27889912 )
2017
45
Genetic variation in long noncoding RNAs and the risk of nonalcoholic fatty liver disease. ( 28206970 )
2017
46
Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets. ( 28948002 )
2017
47
Nonalcoholic Fatty Liver Disease Incidence and Impact on Metabolic Burden and Death: a 20 Year-Community Study. ( 28941364 )
2017
48
Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study. ( 28946547 )
2017
49
Clinical penetrance in hereditary hemochromatosis: estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes. ( 28771247 )
2017
50
CD151 supports VCAM-1-mediated lymphocyte adhesion to liver endothelium and is upregulated in chronic liver disease and hepatocellular carcinoma. ( 28473332 )
2017

Variations for Liver Disease

Expression for Liver Disease

Search GEO for disease gene expression data for Liver Disease.

Pathways for Liver Disease

GO Terms for Liver Disease

Cellular components related to Liver Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 ADIPOQ AFP ALB F2 GGT1